Related by context. All words. (Click for frequent words.) 73 imetelstat 72 HGS ETR1 72 PEG SN# 71 PXD# 71 OXi# 71 INCB# [001] 71 HGS ETR2 71 ENMD # 70 AQ4N 70 pertuzumab 70 MGCD# [001] 70 Azedra 69 alvespimycin 69 telomerase inhibitor drug 69 AP# [003] 69 Sym# 69 anti leukemic 69 BRAF inhibitor 69 PSMA ADC 68 AEG# 68 Xanafide 68 CA4P 68 ganetespib 68 pan HDAC inhibitor 68 angiogenesis inhibitor 68 OMP #M# 68 CD# antibody [001] 68 MEK inhibitors 68 obatoclax 68 dacetuzumab 68 LEP ETU 67 mapatumumab 67 entinostat 67 elotuzumab 67 enzastaurin 67 tyrosine kinase inhibitor 67 HGS# 67 GRNVAC1 67 antitumor activity 67 histone deacetylase HDAC inhibitor 67 telomerase therapeutic 67 protein kinase inhibitor 67 oral prodrug 67 JAK inhibitor 67 kinase inhibitor 67 elesclomol 67 Panzem R NCD 67 Symadex 66 MEK inhibitor 66 CCX# 66 INGN 66 milatuzumab 66 SAR# [004] 66 Aplidin 66 CYC# 66 MGd 66 antitumor 66 Imprime PGG 66 depsipeptide 66 investigational humanized monoclonal antibody 66 tanespimycin 66 huC# DM4 66 vaccine GRNVAC1 66 YONDELIS 66 XmAb# 66 BAY #-# 66 HER2 antibody 66 flavopiridol 66 talabostat 66 Panzem 66 deforolimus 66 CYT# 66 PEGPH# 66 proteasome inhibitor 66 AMD# [003] 66 anti proliferative 66 cediranib 66 lintuzumab 66 drug conjugate 66 favorable pharmacokinetic profile 66 RGB # 66 OncoVEX GM CSF 66 metaglidasen 66 Tarvacin TM 66 sorafenib Nexavar 66 IMC A# 66 MDV# 66 R#/MEM # 66 hematological malignancies 66 HspE7 66 voreloxin 66 Seliciclib 66 orally administered inhibitor 66 CR# vcMMAE 66 eniluracil 66 bortezomib 65 antiangiogenic activity 65 preclinically 65 evaluating tivozanib 65 CBLC# 65 Aurora kinase 65 Carfilzomib 65 selective kinase inhibitor 65 forodesine 65 preclinical studies 65 Atiprimod 65 bortezomib Velcade 65 xenograft models 65 phase IIb clinical 65 vascular disrupting agent 65 Tarvacin 65 etoposide 65 mTOR inhibitors 65 antitumor effects 65 Omacetaxine 65 PRT# 65 APOPTONE 65 EGFr 65 Panzem R 65 HCD# [002] 65 EOquin TM 65 CTLA 4 65 ON #.Na 65 decitabine 65 docetaxel Taxotere R 65 Gleevec resistant 65 Phase Ib 65 novel peptide 65 iniparib 65 CCR2 65 bevacizumab Avastin ® 65 indibulin 65 Chemophase 65 Panzem NCD 65 Amrubicin 65 antibody MT# 65 HCV protease 65 rNAPc2 65 orally bioavailable 65 MAGE A3 ASCI 65 EGF receptor 65 vidofludimus 65 investigational monoclonal antibody 65 mertansine 65 inhibitory effects 65 teriflunomide 65 #ME# 65 RDEA# 65 CTCE 65 molecularly targeted 64 sapacitabine 64 Apoptone 64 docetaxel chemotherapy 64 Actilon 64 Aflibercept 64 JAK2 64 OvaRex R 64 MOZOBIL 64 PLK1 SNALP 64 seliciclib 64 partial agonist 64 pharmacodynamic PD 64 nonclinical studies 64 selective androgen receptor modulator 64 Annamycin 64 targeting CD# 64 atacicept 64 alkylating agent 64 HuLuc# 64 PKC# 64 Phase Ib II 64 chemotherapeutic agent 64 XL# [003] 64 Virulizin ® 64 GMX# 64 gemcitabine Gemzar 64 erlotinib Tarceva ® 64 pomalidomide 64 IAP inhibitors 64 vorinostat 64 tubulin inhibitor 64 Nanobody 64 immunomodulator 64 MyVax R 64 Phase #b/#a clinical 64 neratinib 64 Traficet EN 64 REOLYSIN ® 64 gemcitabine 64 cilengitide 64 MAb 64 Phase Ib study 64 hA# 64 Phase 1b 64 PSN# [002] 64 IMA# 64 pharmacodynamic 64 paclitaxel Taxol ® 64 HSP# inhibitor 64 XL# inhibits 64 antiangiogenic 64 Aplidin R 64 OncoVEX 64 vascular disrupting agents 64 Phase 2a trial 64 solithromycin 64 Bortezomib 64 chemotherapeutics 64 axitinib 64 Kahalalide F 64 ISIS # 64 CDK inhibitor 64 Alocrest 64 pharmacodynamics 64 IAP inhibitor 64 CEQ# 64 oxidative stress inducer 64 GAP #B# 64 ENMD 64 Phase #/#a trial 64 Lenocta 64 Enzastaurin 64 erlotinib Tarceva 64 Preclinical studies suggest 63 IFN α 63 Quinamed 63 IFN alpha 63 pralatrexate 63 cancer immunotherapies 63 ixabepilone 63 VNP#M 63 docetaxel Taxotere 63 OMP #R# 63 proteasome inhibitors 63 TLR8 agonist 63 chemotherapeutic drug 63 HDAC inhibitors 63 TKM ApoB 63 pegylated liposomal doxorubicin 63 Preclinical studies 63 Cloretazine R VNP#M 63 preclinical efficacy 63 Blinatumomab 63 hypoxia inducible factor 63 ApoB SNALP 63 Perifosine 63 cetuximab Erbitux ® 63 systemic RNAi therapeutic 63 temozolomide 63 custirsen 63 M2 subunit 63 FGFR 63 NXL# 63 Phase Ib clinical trials 63 ELACYT 63 panobinostat 63 menadione 63 TNFerade 63 uric acid lowering 63 AKT inhibitor 63 glucagon receptor 63 protein tyrosine phosphatase 1B 63 isoform selective 63 Zolinza 63 ALN VSP 63 PI3K inhibitor 63 ongoing Phase 1b 63 adecatumumab 63 belinostat 63 liposomal formulation 63 PEG Interferon lambda 63 Factor VIIa 63 PNP inhibitor 63 tesetaxel 63 signal transduction inhibitor 63 otelixizumab 63 dasatinib Sprycel 63 anti angiogenic 63 Targretin 63 VEGFR2 63 anticancer activity 63 trastuzumab DM1 T DM1 63 PS# [001] 63 trabectedin 63 Imetelstat 63 sorafenib Nexavar ® 63 Onconase 63 zanolimumab 63 delafloxacin 63 generation Hsp# inhibitor 63 SCH # 63 PI3K/mTOR 63 Phase Ib clinical 63 HCV protease inhibitor 63 Geron telomerase inhibitor 63 CLORETAZINE TM VNP#M 63 JAK2 inhibitor 63 immunomodulatory 63 JAK1 63 PDE4 inhibitor 63 Bezielle 63 ara C 63 Cloretazine VNP#M 63 Cloretazine 63 HER2 positive metastatic breast 63 Tyrima 63 nucleoside 63 IRX 2 63 Azedra TM 63 TELCYTA 63 IGF 1R 63 huN# DM1 63 humanized antibody 63 gefitinib Iressa 63 NEUGENE 63 RG# [001] 63 IL #E 63 anticancer agent 63 gemcitabine cisplatin 63 idarubicin 63 dose escalation trial 63 ascending dose 63 ponatinib 63 Dapagliflozin 63 humanized anti 63 relapsed multiple myeloma 63 ToGA 63 receptor tyrosine kinase inhibitor 63 pharmacodynamic markers 63 registrational trial 63 receptor inhibitor 62 Hsp# inhibitor 62 pro angiogenic 62 Pertuzumab 62 vivo efficacy 62 visilizumab 62 trastuzumab Herceptin R 62 BNC# 62 selective inhibition 62 HuMax CD# 62 reslizumab 62 nab paclitaxel 62 TRIOLEX 62 histone deacetylase inhibitor 62 multi kinase inhibitor 62 selective modulator 62 delta isoform 62 davunetide intranasal AL 62 fosbretabulin 62 LY# [003] 62 palifosfamide 62 galiximab 62 HDAC inhibition 62 Phase 2b clinical 62 blinatumomab 62 ATL# [001] 62 immune modulating 62 crizotinib PF # 62 HuMax EGFr 62 VEGF inhibitors 62 gamma secretase inhibitor 62 AAG geldanamycin analog 62 corticosteroid dexamethasone 62 interferon IFN 62 daclizumab 62 oral picoplatin 62 TG# [003] 62 targeted antifolate 62 Angiolix 62 HuMax CD4 62 CTGF 62 sunitinib malate 62 Cloretazine ® 62 EpCAM 62 dose cohorts 62 Janus Kinase 62 NFkB 62 hematological cancers 62 bortezomib Velcade ® 62 Deforolimus 62 HER3 62 imatinib Gleevec ® 62 zalutumumab 62 Androxal TM 62 PARP inhibitor 62 PDX pralatrexate 62 EndoTAG TM -1 62 VEGF receptor 62 Cloretazine R 62 Tamibarotene 62 K ras mutations 62 Sudhir Agrawal D.Phil 62 mecamylamine 62 Phase #b/#a 62 PLX# 62 antisense oligonucleotides 62 solid tumors 62 Exherin TM 62 mda 7 62 viral kinetics 62 compound AEZS 62 Neuradiab 62 phase IIa clinical 62 tipifarnib 62 PI3K/Akt pathway inhibitor 62 potent anti angiogenic 62 BiTE 62 TREANDA 62 CYT# potent vascular disrupting 62 anticancer agents 62 factor TNF 62 intratumoral injection 62 anti CD3 antibody 62 TRAIL receptor antibodies 62 alpha folate receptor 62 cytostatic 62 imetelstat GRN#L 62 humanized monoclonal antibodies 62 IMP# 62 Vidaza ® 62 orally dosed 62 JAK inhibitors 62 cannabinor 62 kinase inhibition 62 EGFR HER2 62 systemically administered 62 carfilzomib 62 anticancer compound 62 potent inhibitor 62 NEUVENGE 62 Asentar 62 Vitaxin 62 potent anticancer 62 CRLX# 62 perifosine 62 BRIM2 62 GVAX ® 62 5 fluorouracil leucovorin 62 JVRS 62 humanized monoclonal antibody 62 phase IIb trial 62 dose escalation Phase 62 FOLFOX6 chemotherapy regimen 62 Marqibo 62 phase Ib 62 MYDICAR ® 62 Curaxin CBLC# 62 Xcellerated T Cells 62 OHR/AVR# 62 bafetinib 62 c MET 62 TELINTRA 62 VEGF Trap 62 biodistribution 62 pro apoptotic 62 antiproliferative 62 TPI ASM8 62 PF # [001] 62 MT#/MEDI-# 62 amrubicin 62 ocular formulation 62 nucleotide analog 62 sodium glucose cotransporter 62 MEK inhibitor RDEA# 62 ZK EPO 62 sorafenib tablets 62 EGFR inhibitors 62 Xelox 62 trastuzumab Herceptin 62 cetuximab Erbitux R 62 Trofex 62 S/GSK# 62 IMGN# 62 novel topoisomerase 62 sipuleucel T 62 eltrombopag 62 Vandetanib 62 HGS ETR1 mapatumumab 62 chemotherapeutic agents 62 oral ridaforolimus 62 DOS# 62 immunotherapeutic agent 62 AEGR 62 KRN# 62 Phase 1b trial 62 Curaxin 62 Romidepsin 62 nucleoside analog 62 TRC# 62 cytotoxic 61 Trastuzumab 61 Erlotinib 61 BiTE antibodies 61 A3 adenosine receptor 61 CoFactor 61 Solazed 61 Leukine 61 PCK# 61 azacitidine 61 CD# CEA 61 antibody MAb 61 Talabostat 61 LY# [002] 61 Voreloxin 61 INCB# [002] 61 antitumor effect 61 humanised monoclonal antibody 61 tyrosine kinase inhibitors 61 novel VDA molecule 61 vinca alkaloid 61 BAL# [001] 61 TNFalpha 61 anti CD3 61 PARP inhibitors 61 Dasatinib 61 farletuzumab 61 radiation sensitizer 61 bendamustine 61 telomerase inhibitor 61 TACI Ig 61 Taxotere chemotherapy 61 retaspimycin 61 Vidofludimus 61 Epratuzumab 61 GLP toxicology studies 61 thymalfasin 61 PEGylated interferon 61 apoptotic pathway 61 Tarceva TM 61 generation antisense 61 FK# 61 bicalutamide 61 doxorubicin 61 hematologic malignancies 61 multitargeted 61 Fibroblast Growth Factor Receptor 61 non nucleoside inhibitor 61 small molecule tyrosine 61 maximally tolerated dose 61 ALN TTR 61 ganaxolone 61 TTR gene 61 #I TM# 61 CCR9 61 Virulizin R 61 phase 2a 61 HIF PHI 61 ZOLINZA 61 DXL# 61 MET amplification 61 relapsed MM 61 mTOR inhibitor 61 Insegia 61 WT1 61 NEUGENE antisense 61 CD# monoclonal antibody 61 immune stimulatory 61 Zybrestat 61 demethylating agents 61 Smac mimetics 61 Proxinium TM 61 methionine aminopeptidase 61 factor HGF 61 Elotuzumab 61 antitumor efficacy 61 Genasense ® oblimersen 61 Pralatrexate 61 HDACi 61 cetuximab Erbitux 61 gemcitabine carboplatin 61 pharmacodynamic effects 61 anti CTLA 61 CORT # 61 FOLFOX6 61 brentuximab vedotin SGN 61 TRX1 61 FTY# 61 preclinical 61 CENP E 61 INT# [002] 61 imatinib resistant 61 miR #a [002] 61 JAK3 61 Telintra 61 PI3K Akt 61 ARRY 61 NOD SCID mice 61 carboplatin paclitaxel 61 radezolid 61 AZD# 61 oral proteasome inhibitor 61 sunitinib Sutent ® 61 liposome encapsulated 61 cytotoxic agents 61 BCX# 61 T#I mutant 61 hematological tumors 61 picoplatin 61 IL# PE#QQR 61 immunostimulatory 61 BrachySil TM 61 EGFR receptor 61 c MYC 61 cutaneous T cell 61 imatinib Gleevec 61 KSP inhibitor 61 ERK1 2 61 inhibit metastasis 61 HDAC Inhibitor 61 metastatic colorectal 61 erythropoietic 61 T DM1 61 MetMAb 61 HER1 61 tumor xenograft models 61 ZD# [001] 61 BiTE antibody 61 epigenetic therapies 61 BRAF kinase 61 MGCD# [002] 61 Azixa 61 RAV# 61 Gefitinib 61 novel histone deacetylase 61 tesmilifene 61 samalizumab 61 DAVANAT 61 thrombopoietin 61 PEGylated 61 mAbs 61 Guanilib 61 TNFα 61 rBChE 61 paclitaxel Taxol 61 Omacetaxine mepesuccinate 61 TOCOSOL Paclitaxel 61 SERMs 61 PI3 kinase inhibitors 61 Doxil 61 Talactoferrin 61 PEG PAL 61 peptide antigens 61 pharmacodynamic properties 61 bortezomib Velcade R 61 PRTX 61 myeloproliferative disorders 61 standard chemotherapy regimen 61 apremilast 61 TOCOSOL Camptothecin 61 LBH# 61 p# biomarker 61 peptibody 61 potent antiproliferative 61 Ceflatonin 61 immunotoxin 61 GM CSF 61 taxanes 61 pDCs 61 Leukine ® 61 TRV# [001] 61 brostallicin 61 romidepsin 61 JAK2 inhibitors 60 AMN# [001] 60 CD4 monoclonal antibody 60 Fc fusion protein 60 Nexavar ® 60 Neuvenge 60 lumiliximab 60 2 methoxyestradiol 60 induces apoptosis 60 Archexin 60 mitogen activated ERK kinase 60 volociximab 60 anticancer therapies 60 DNA intercalator 60 tolevamer 60 kinase inhibitors 60 nucleoside reverse transcriptase inhibitor 60 Amigal 60 multicenter Phase II 60 Interferon alpha 60 VA# [002] 60 EGFR TKIs 60 CUDC 60 Azacitidine 60 PD LID 60 eculizumab 60 TLK# 60 Epothilones 60 celgosivir 60 MT# MEDI 60 HQK 60 nanopharmaceutical 60 vWF 60 XL# XL# XL# 60 relapsed refractory multiple myeloma 60 secretory phospholipase A2 sPLA2 60 antiangiogenic agent 60 oral deforolimus 60 nanoviricides 60 dasatinib 60 cyclin dependent kinases CDKs 60 factor Xa 60 taxane chemotherapy 60 Allovectin 7 60 Hsp# inhibition 60 azacytidine 60 Triolex 60 interferon lambda 60 vascular disrupting 60 demonstrated antitumor activity 60 Akt inhibitor 60 immunotoxins 60 anticancer therapy 60 antiproliferative effects 60 synthetic retinoid 60 Th2 cytokines 60 K RAS 60 gemcitabine Gemzar ® 60 Eg5 60 velafermin 60 Elvitegravir 60 SPC# [001] 60 NeuroVax TM 60 interferon gamma 1b 60 apoptosis proteins 60 Thiovir 60 IgG1 antibody 60 midstage trials 60 EOquin 60 adecatumumab MT# 60 AACR NCI EORTC 60 heavily pretreated 60 immunotherapeutic 60 pharmacokinetics PK 60 proteasome inhibitor bortezomib 60 epothilones 60 BZL# 60 Tesetaxel 60 Phase 2b trial 60 Multimeric 60 pegfilgrastim 60 inhibitor RG# 60 anticancer 60 IgG1 monoclonal antibody 60 ProLindac 60 leukemia AML 60 temsirolimus 60 posaconazole 60 potent inhibition 60 trastuzumab 60 TBC# 60 liposomal doxorubicin 60 Taxotere docetaxel 60 FOLFOX chemotherapy 60 HDAC 60 Hsp# inhibitors 60 GRN# 60 bevacizumab Avastin R 60 HDAC inhibitor 60 goserelin 60 cytoprotective 60 replicon 60 mRCC 60 Fx #A 60 Vidaza azacitidine 60 tumor vasculature 60 rhIL 7 60 Pharmacokinetics PK 60 pharmacodynamics PD 60 inhibit EGFR 60 riociguat 60 generation purine nucleoside 60 Pathway Inhibitor 60 Dacogen injection 60 personalized immunotherapy 60 GW# [003] 60 ICA # 60 tolerability profiles 60 Liposomal 60 Pemetrexed 60 therapeutic monoclonal antibody 60 p# inhibitors 60 pharmacokinetic PK 60 cytarabine 60 targeted radiotherapeutic 60 thalidomide Thalomid 60 cisplatin resistant 60 topotecan 60 TRAIL R2 60 heparanase 60 glufosfamide 60 Janus kinase 60 apoptosis inducer 60 5 FU leucovorin 60 olaparib 60 epithelial tumors 60 Exelixis compounds 60 selectively inhibits 60 L Annamycin 60 ALN PCS 60 anti EGFR antibody 60 tafamidis 60 tranilast 60 EndoTAGTM 1 60 Pazopanib 60 docetaxel Taxotere ® 60 S1P 60 motesanib 60 ErbB 60 assessing T DM1 60 estramustine 60 selective agonist 60 interferon alfa 60 CD#L 60 erlotinib 60 chimeric monoclonal antibody 60 imatinib therapy 60 cell lymphoma CTCL 60 FOLOTYN ® 60 MLN# 60 small molecule defensin 60 nilotinib 60 oral Azacitidine 60 polymerase inhibitor 60 monoclonal 60 immune modulator 60 tiuxetan 60 refractory chronic lymphocytic 60 EFAPROXYN 60 cytotoxicity 60 VEGF receptors 60 reversible inhibitor 60 SUCCEED trial 60 next generation URAT1 60 antiapoptotic 60 endostatin 60 rhIGFBP 3 60 Hedgehog pathway 60 siRNA mediated 60 Rebif ® 60 MNTX 60 Phase 2a clinical 60 microtubule inhibitor 60 myelofibrosis polycythemia vera 60 CD3 monoclonal antibody 60 DAPT 60 pemetrexed 60 mGluR2 NAM 60 antiangiogenesis 60 Vaxfectin R 60 Lisofylline 60 anti fibrotic 60 APTIVUS 60 leading oral taxane 60 antiangiogenic therapy 60 Anacetrapib 60 muscarinic 60 PDGFR 60 nitazoxanide 60 generation antisense inhibitor 60 nucleoside analogs 60 metastatic CRC 60 Phase 1b clinical 60 resistant ovarian cancer 60 Protexia ® 60 varespladib 60 tumor antigen 60 #beta HSD1 60 IMC #B 60 CTAP# Capsules 60 Hsp# Inhibitor 60 IL 1ß 60 OvaRex ® MAb 60 Darinaparsin 60 sphingosine 1 60 anti amnesic 60 aflibercept 60 LHRH antagonists 60 MVA BN R 60 refractory AML 60 ALN TTR# 60 phase IIb 60 Taxotere ® 60 GSK3B 60 ALB # 60 EGFR tyrosine kinase inhibitors 60 p# inhibitor 60 dose escalation 60 trastuzumab DM1 60 tezampanel 60 chemopreventive agent 60 PI3K inhibitors 60 thrombin receptor 60 GALNS 60 TRAIL induced apoptosis 60 alemtuzumab Campath 60 compound perifosine 60 Hedgehog Pathway Inhibitor 60 talactoferrin 60 hypoxia activated prodrug 60 XOMA 3AB 60 vismodegib 60 effector function 60 PROSTVAC TM 60 hedgehog pathway 60 anionic backbone 60 epothilone 60 busulfan 60 CINOD 60 Romiplostim 60 polycythemia vera PV 60 Telcyta 60 Gliadel Wafer 60 sigma receptors 60 urocortin 2 59 palifosfamide Zymafos TM 59 thymidylate synthase 59 XL# XL# 59 induce apoptosis 59 dose limiting toxicities 59 peptidomimetic 59 TNF α 59 Aptivus ® 59 potent cytotoxic 59 Phase IIa trial 59 Fodosine 59 lintuzumab SGN 59 lenalidomide Revlimid R 59 Amplimexon 59 combinability 59 mTOR inhibition 59 vivo potency 59 Valortim ® 59 MCSP respectively 59 Debio 59 FLT3 59 TLR9 59 PDGF receptor 59 oral antiviral 59 sulodexide 59 ONCONASE 59 EndoTAG 59 preclinical models 59 androgen receptor AR 59 Copegus ribavirin 59 recurrent glioblastoma multiforme 59 novel anticancer 59 VQD 59 oral Xeloda 59 virus HCV protease inhibitor 59 Gemzar ® 59 vinorelbine 59 TransVax TM 59 ProSavin 59 HDL Mimetic Peptide 59 Interferon alfa 59 aplindore 59 KNS # 59 CDK inhibitors 59 trastuzumab Herceptin ® 59 calcitriol 59 adalimumab Humira 59 cMET 59 AeroLEF TM 59 maturation inhibitor 59 Kinoid 59 myelofibrosis 59 Allovectin 7 ® 59 elacytarabine 59 pharmacokinetic profile 59 daunorubicin 59 androgen independent 59 cancer vaccine Norelin 59 Fulvestrant 59 LHRH receptor positive 59 gastrin 59 alefacept 59 CRx 59 Fludara 59 lenalidomide dexamethasone 59 mGluR5 negative 59 PROSTASCINT R 59 Neulasta ® 59 integrase inhibitor 59 teduglutide 59 INCB# [003] 59 lesinurad 59 Synavive 59 HCV replication 59 TRO# 59 veltuzumab 59 avosentan 59 L BLP# 59 bevacizumab Avastin 59 Zalypsis 59 NF kB pathway 59 selective antagonist